42 completed. 42 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 42 | Completed 42 |
| Phase 1 | 5 | Completed 5 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations trametinib, laboratory biomarker analysis, pharmacological study - Recurrent Melanoma, Stage IIIB Melanoma | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 9 | 2015-01-01 | 2021-05-28 |
| Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis - Liver Metastases, Lung Metastases | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 8 | 2014-09-05 | 2024-05-21 |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic cytology specimen collection procedure, MEK 162 therapy or molecularly targeted therapy, therapeutic procedure - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | Yale University | 49 | 2014-05-01 | 2020-01-02 |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Epacadostat, MELITAC 12.1 Peptide Vaccine - Mucosal Melanoma, Recurrent Melanoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 11 | 2013-09-13 | 2018-06-08 |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 88 | 2013-03-25 | 2026-07-21 |
| Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept - Metastatic Melanoma, Recurrent Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 84 | 2011-01-18 | 2019-05-10 |
| Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery temozolomide, flow cytometry, staining method - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Completed | Mayo Clinic | 25 | 2011-01-01 | 2020-10-22 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Cisplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 14 | 2010-08-01 | 2019-11-18 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PD-0332991 - Adult Solid Tumor, Adenocarcinoma of the Colon | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 304 | 2009-10-01 | 2021-03-11 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study - Recurrent Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 13 | 2009-04-03 | 2018-10-16 |
| MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma Laboratory Biomarker Analysis, Selumetinib - Recurrent Melanoma, Stage III Skin Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 167 | 2009-03-01 | 2015-08-11 |
| Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma ipilimumab, cyclophosphamide, biopsy - Recurrent Melanoma, Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 10 | 2009-02-01 | 2017-04-19 |
| Viral Therapy in Treating Patients With Metastatic Melanoma wild-type reovirus - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2008-04-01 | 2014-04-22 |
| Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma Bevacizumab, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Melanoma, Stage IIIB Skin Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2008-01-01 | 2017-06-09 |
| Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide - Recurrent Melanoma, Stage IV Melanoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 10 | 2007-09-01 | 2017-02-15 |
| Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery sorafenib tosylate, tipifarnib, temsirolimus - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 109 | 2007-08-01 | 2014-05-20 |
| VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery ziv-aflibercept, pharmacological study - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2007-06-01 | 2018-05-24 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery imatinib mesylate, laboratory biomarker analysis - Acral Lentiginous Malignant Melanoma, Recurrent Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2007-04-01 | 2014-12-23 |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma dasatinib - Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2006-12-01 | 2014-05-15 |
Showing 20 of 42. Sign in to see all of them.
Melanoma (42) · Uveal Melanoma (7) · Neoplasms (4) · Skin Neoplasms (4) · Brain Neoplasms (2) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, Non-Hodgkin (1) · Neuroblastoma (1) · Neuroectodermal Tumors, Primitive, Peripheral (1) · Osteosarcoma (1) · Rectal Neoplasms (1)
Neoplasms by Histologic Type (42) · Neoplasms by Site (42) · Neoplasms, Germ Cell and Embryonal (42) · Neoplasms, Nerve Tissue (42) · Neuroectodermal Tumors (42) · Neuroendocrine Tumors (42) · Nevi and Melanomas (42) · Skin Diseases (42) · Skin and Connective Tissue Diseases (42) · Neoplasms (38) · Skin Neoplasms (38) · Eye Diseases (7) · Eye Neoplasms (7) · Uveal Diseases (7) · Uveal Neoplasms (7)
Bevacizumab (5) · CTLA-4 Antigen (4) · Interleukin-2 (4) · Ipilimumab (4) · aldesleukin (4) · Biopsy (3) · Temozolomide (3) · Bortezomib (2) · Carboplatin (2) · Cyclophosphamide (2) · Disulfides (2) · Flow Cytometry (2) · Imatinib Mesylate (2) · Immunoglobulin G (2) · Immunohistochemistry (2)
National Cancer Institute (NCI) (30) · Fred Hutchinson Cancer Center (3) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Case Comprehensive Cancer Center (1) · Mayo Clinic (1) · Ohio State University Comprehensive Cancer Center (1) · University of Southern California (1) · Vanderbilt-Ingram Cancer Center (1) · Vical (1) · Yale University (1)
United States (40) · Canada (3)
Ahmad Tarhini (3) · Craig Slingluff (2) · Patrick Hwu (2) · Svetomir Markovic (2) · Thomas Gajewski (2) · William Carson (2) · Amy Weise (1) · Anna Pavlick (1) · Aude Chapuis (1) · Barbara A. Pockaj, MD (1) · Cassian Yee (1) · Crystal L Mackall (1) · Douglas Johnson (1) · Elaine McWhirter (1) · Ernest C. Borden, MD (1)
PMID 20098694, PMID 21642685, PMID 23228035, PMID 23620404, PMID 24047116, PMID 24464266, PMID 24817603, PMID 27269940, PMID 27368067, PMID 31401903, PMID 32192573, PMID 32641862, PMID 32692450, PMID 33861486
U10CA031946 (4), N01CM62206 (3), P30CA008748 (3), N01CM00070 (2), N01CM62201 (2), N01CM62203 (2), N01CM62205 (2), N01CM62209 (2), P30CA033572 (2), K12CA076930 (1), N01CM00038 (1), N01CM00071 (1), N01CM17103 (1), N01CM17104 (1), N01CM62204 (1)